BioSpace News Archive

Business

Nanomerics Expands and Moves to New Laboratories

Nanomerics Ltd., a private speciality pharmaceutical company and University College London spin out, announced that the Company had invested significantly in its operations, and moved to new laboratories and offices in North London.

February 17, 2022

·

4 min read

Business

Syneos Health Reports Fourth Quarter and Full Year 2021 Results

Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today reported financial results for the three and twelve months ended December 31, 2021.

February 17, 2022

·

27 min read

Business

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

Immunic, Inc. today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2021, including a corporate update, on Thursday, February 24, 2022, before the opening of the U.S. financial markets.

February 17, 2022

·

4 min read

Business

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021

Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2021.

February 17, 2022

·

24 min read

Business

Neumora Expands Precision Neuroscience Pipeline with Novel M4 Receptor Modulator Program Through Exclusive License Agreement with Vanderbilt University

Neumora to develop and commercialize M4-selective muscarinic receptor positive allosteric modulator program for schizophrenia and other neuropsychiatric disorders.

February 17, 2022

·

4 min read

Biotech Bay

Aridis’ Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals

Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced that both of its fully human monoclonal antibodies in the AR-701 cocktail neutralized the SARS-CoV-2 Omicron variant.

February 17, 2022

·

8 min read

Drug Development

Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis

Evelo Biosciences, Inc. today announced that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis.

February 17, 2022

·

6 min read

Microbix Presenting at Capital Conference in B.C.Meetings with Growth-Oriented Investors, February 18-20, 2022

Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it will be presenting to equity investors at the Whistler Capital Conference, organized by Capital Event Management Ltd. and being hosted at the Fairmont Chateau Whistler, in Whistler, B.C., February 18-20, 2022.

February 17, 2022

·

4 min read

Business

NXT-ID Appoints Key Executives to Support Product Suite Development and Company Growth

NXT-ID, Inc. (NASDAQ: NXTD), provider of personal emergency response systems (PERS), health communications devices and IoT technology, today announces it has appointed Mark Archer as Chief Financial Officer, and Rafael Saavedra as VP of Engineering.

February 17, 2022

·

6 min read

Business

Seegene Announces Q4 and Full-Year 2021 Financial Results

Seegene Inc. today announced full-year 2021 financial results that marked an all-time high record with total sales increasing 22% year-over-year (YoY) to KRW 1.37 trillion (approx. US$1.14 billion).

February 17, 2022

·

4 min read